PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases

• Esperanza Martín-Sánchez,

  Affiliations Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, Cancer Genomics Group, Marqués de Valdecilla Research Institute (IDIVAL) & Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

  ⨯
• Lina Odqvist,

  Affiliation Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
• Socorro M. Rodríguez-Pinilla,

  Affiliation Pathology Department, Fundación Jiménez Díaz, Madrid, Spain

  ⨯
• Margarita Sánchez-Beato,

  Affiliation Onco-hematology Area, Instituto de Investigación Sanitaria Hospital Universitario Puerta de Hierro - Majadahonda, Madrid, Spain

  ⨯
• Giovanna Roncador,

  Affiliation Monoclonal Antibodies Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
• Beatriz Domínguez-González,

  Affiliation Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
• Carmen Blanco-Aparicio,

  Affiliation Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
• Ana M. García Collazo,

  Affiliation Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
• Esther González Cantalapiedra,

  Affiliation Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
• Joaquín Pastor Fernández,

  Affiliation Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
• Soraya Curiel del Olmo,

  Affiliation Cancer Genomics Group, Marqués de Valdecilla Research Institute (IDIVAL) & Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

  ⨯
• Helena Pisonero,

  Affiliation Cancer Genomics Group, Marqués de Valdecilla Research Institute (IDIVAL) & Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

  ⨯
• Rebeca Madureira,

  Affiliation Cancer Genomics Group, Marqués de Valdecilla Research Institute (IDIVAL) & Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

  ⨯
• Carmen Almaraz,

  Affiliation Cancer Genomics Group, Marqués de Valdecilla Research Institute (IDIVAL) & Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

  ⨯
• Manuela Mollejo,

  Affiliation Pathology Department, Hospital Virgen de la Salud, Toledo, Spain

  ⨯
• F. Javier Alves,

  Affiliation Pathology Department, Hospital La Paz, Madrid, Spain

  ⨯
• Javier Menárguez,

  Affiliation Pathology Department, Hospital Gregorio Marañón, Madrid, Spain

  ⨯
• Fernando González-Palacios,

  Affiliation Pathology Department, Hospital Ramón y Cajal, Madrid, Spain

  ⨯
• José Luis Rodríguez-Peralto,

  Affiliation Pathology Department, 12 de Octubre University Hospital, Medical School Universidad Complutense, Instituto i+12, Madrid, Spain

  ⨯
• Pablo L. Ortiz-Romero,

  Affiliation Dermatology Department, 12 de Octubre University Hospital, Medical School Universidad Complutense, Instituto i+12, Madrid, Spain

  ⨯
• Francisco X. Real,

  Affiliation Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
• Juan F. García,

  Affiliation Translational Research Laboratory, M. D. Anderson Cancer Center Madrid, Madrid, Spain

  ⨯
• James R. Bischoff,

  Affiliation Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

  ⨯
•  [ ... ],
• Miguel A. Piris

  * E-mail: mapiris@humv.es

  Affiliations Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, Cancer Genomics Group, Marqués de Valdecilla Research Institute (IDIVAL) & Pathology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

  ⨯
• [ view all ]
• [ view less ]